These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19962909)

  • 1. A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity.
    Vasan S; Tsuji M
    Semin Immunol; 2010 Apr; 22(2):87-96. PubMed ID: 19962909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
    Padte NN; Li X; Tsuji M; Vasan S
    Clin Immunol; 2011 Aug; 140(2):142-51. PubMed ID: 21185784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of invariant NKT cells at the interface of innate and adaptive immunity.
    Cerundolo V; Kronenberg M
    Semin Immunol; 2010 Apr; 22(2):59-60. PubMed ID: 20172739
    [No Abstract]   [Full Text] [Related]  

  • 4. CD1d-Restricted Natural Killer T Cells Are Preserved in Indian Long-Term Nonprogressors.
    Singh D; Ghate M; Godbole S; Kulkarni S; Thakar M
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):e104-e112. PubMed ID: 28650939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.
    Liu Z; Guo J
    Carbohydr Res; 2017 Nov; 452():78-90. PubMed ID: 29080431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection.
    Moll M; Kuylenstierna C; Gonzalez VD; Andersson SK; Bosnjak L; Sönnerborg A; Quigley MF; Sandberg JK
    Eur J Immunol; 2009 Mar; 39(3):902-11. PubMed ID: 19197939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M
    J Vis Exp; 2007; (10):635. PubMed ID: 18989407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection.
    Kuylenstierna C; Snyder-Cappione JE; Loo CP; Long BR; Gonzalez VD; Michaëlsson J; Moll M; Spotts G; Hecht FM; Nixon DF; Sandberg JK
    Scand J Immunol; 2011 Feb; 73(2):141-6. PubMed ID: 21198755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut.
    Marrero I; Maricic I; Feldstein AE; Loomba R; Schnabl B; Rivera-Nieves J; Eckmann L; Kumar V
    Front Immunol; 2018; 9():2082. PubMed ID: 30254647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant
    Genardi S; Visvabharathy L; Cao L; Morgun E; Cui Y; Qi C; Chen YH; Gapin L; Berdyshev E; Wang CR
    Front Immunol; 2020; 11():610010. PubMed ID: 33312179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.
    Venkataswamy MM; Porcelli SA
    Semin Immunol; 2010 Apr; 22(2):68-78. PubMed ID: 19945296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells.
    Zajonc DM; Kronenberg M
    Immunol Rev; 2009 Jul; 230(1):188-200. PubMed ID: 19594637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of CD1d-restricted natural killer T cells in chronic HIV type 1 clade C infection.
    Mureithi MW; Cohen K; Moodley R; Poole D; Mncube Z; Kasmar A; Moody DB; Goulder PJ; Walker BD; Altfeld M; Ndung'u T
    AIDS Res Hum Retroviruses; 2011 May; 27(5):501-9. PubMed ID: 20942750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis.
    Arora P; Foster EL; Porcelli SA
    Adv Exp Med Biol; 2013; 783():199-223. PubMed ID: 23468111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Janus Face of NKT Cell Function in Autoimmunity and Infectious Diseases.
    Torina A; Guggino G; La Manna MP; Sireci G
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation].
    Watarai H; Tashiro T; Chiba T; Taniguchi M
    Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1584-9. PubMed ID: 21089371
    [No Abstract]   [Full Text] [Related]  

  • 18. Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.
    Papoutselis M; Spanoudakis E
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):358-365. PubMed ID: 32234294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection deregulates Tim-3 expression on innate cells: combination antiretroviral therapy results in partial restoration.
    Finney CA; Ayi K; Wasmuth JD; Sheth PM; Kaul R; Loutfy M; Kain KC; Serghides L
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):161-7. PubMed ID: 23314411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of natural killer T cells by glycolipids.
    Anderson BL; Teyton L; Bendelac A; Savage PB
    Molecules; 2013 Dec; 18(12):15662-88. PubMed ID: 24352021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.